EMPATHY NSCLC: European registry of blood-based molecular profiling in advanced NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

EMPATHY NSCLC is an observational European registry enrolling adults with untreated locally advanced or metastatic NSCLC who are about to start first-line systemic therapy. The registry captures paired plasma- and tissue-based molecular profiling results, treatments chosen, clinical outcomes, and patient-reported outcomes across participating centers. No experimental treatments are assigned; investigators record how molecular testing influences treatment decisions and subsequent outcomes in routine practice. The project aims to describe testing patterns, concordance between plasma and tissue results, and associations between molecular profiles and real-world effectiveness and safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
* Intention-to-initiate first-line tumour therapy for this advanced disease.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
* At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

Exclusion Criteria:

* Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Where it's running

• Université de Lorraine
  Nancy, Lorraine, France Recruiting
• University of Naples "Federico II"
  Naples, Italy Recruiting
• Hôpitaux Universitaires Genève
  Geneva, Canton of Geneva, Switzerland Recruiting
• General Universitario Gregorio Marañon
  Madrid, Spain Not yet recruiting

Study contacts

• Study coordinator: Dr. Christian Meisel, MD PhD
• Email: HederaDxStudies@hederadx.com
• Phone: +41 21 588 16 54

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• AMT-116 vs doctor’s choice in advanced non-squamous NSCLC that is EGFR-wild and progressed after platinum and PD-1/PD-L1 therapy

  This study tests AMT-116 in adults with advanced non-squamous NSCLC that is EGFR-wild, comparing different doses to doctor’s choice after prior platinum and immunotherapy.

  Recruiting Phase 2/3 Multitude Therapeutics Inc. · Port Saint Lucie, Florida and 6 other locations · NCT07718737

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Two-part Phase 1/2 test of ODM-212 combined with other cancer treatments

  This trial tests the oral drug ODM-212, given alone or with approved medicines, to see if it helps adults with advanced mesothelioma, pancreatic cancer, or non-small cell lung cancer.

  Recruiting at 23 sites Phase 1/2 Orion Corporation, Orion Pharma · Los Angeles, California and 22 other locations · NCT07563738

• Vebreltinib with Platinum Chemotherapy as First-line Treatment for MET-Overexpressing NSCLC

  This study tests whether adding vebreltinib to platinum-based chemotherapy can help adults with advanced NSCLC that overexpress MET and lack driver mutations respond to treatment as a first option.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07549061

• Microwave ablation plus tislelizumab and docetaxel for advanced NSCLC after first-line immunotherapy progression

  This treatment tests whether adding microwave ablation to tislelizumab and docetaxel can help people with advanced non‑small cell lung cancer whose disease progressed after first‑line immunotherapy plus chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07528274

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.